The approval of axicabtagene ciloleucel (Yescarta™) for patients with large-B-cell lymphomas whose cancer has progressed after receiving at least two prior treatment regimens was based on trials by the manufacturer that built upon earlier clinical research conducted by NCI’s Center for Cancer Research.
TMIST is a large nationwide clinical trial that researchers hope will answer some important questions about the technologies used to screen for breast cancer.
The Food and Drug Administration (FDA) approved abemaciclib (Verzenio™) for the treatment of some people with advanced or metastatic HR-positive, HER2-negative breast cancer whose disease has progressed after treatment with hormone therapy. The drug is approved for use as a single agent and in combination with fulvestrant, based on the manufacturer’s MONARCH 1 and MONARCH 2 clinical trials.
This phase 2 trial is testing standard therapy (surgery, radiation, and temozolomide) plus the checkpoint inhibitor pembrolizumab with or without a cancer treatment vaccine for patients with newly diagnosed glioblastoma, a common and deadly type of brain tumor.
This page provides helpful information about finding clinical trials you or someone you know may be eligible to join. You’ll find our 6-step guide and a video that explains how to search for and learn more about clinical trials.
Clinical trials play an important role in making progress against all types of cancer. Unfortunately, many people have no idea what a clinical trial is, and to those who have heard of clinical trials, they still can remain a mystery. That is why NCI produces patient education publications about clinical trials. Visit our patient education publications page to find more information about clinical trials.
NCI-Supported Clinical Trials that Are Recruiting Patients
This randomized phase 1/2 trial studies the side effects and best dose of temozolomide when given together with trastuzumab emtansine (T-DM1) and how well they work in preventing the development of brain metastases after stereotactic radiosurgery in patients with HER2-positive breast cancer.
This phase 1/2 trial will assess the safety, tolerability, and feasibility of Pexa-Vec oncolytic virus in combination with the immune checkpoint inhibitors durvalumab and tremelimumab for patients with treatment-resistant metastatic colorectal cancer.
